STOCKS TELEGRAPH

Tag: UPC

Universe Pharmaceuticals Inc. (UPC) Stock Surges Following Progress on Partnership with Kitanihon

Universe Pharmaceuticals Inc. (UPC) stock prices were down by 3.93% as of the market closing on June 29^th, 2021, bringing the price down to USD$2.93 at the end of the trading day. Subsequent after-market fluctuations have seen the stock surge by 17.23%, bringing it up to USD$3.47.

Collaboration with Kitanihon

May 25^th, 2021 saw the company announce having entered into a letter of intent for strategic cooperation with Kitanihon Pharmaceutical. UPC plans to strategically collaborate with a Japanese company that specializes in the research, development, manufacturing, and distribution of healthcare products.

Details of the LOI

As per the LOI, the partnership will seek to establish a flagship store on global.jd.com, which is a popular e-commerce platform in China that offers imported products. UPC will operate the flagship store and sell Kitanihon’s products as an exclusive distributor. Distribution of KP’s products will span Chinese and Southeast Asian markets through respective international e-commerce channels, with the aim of fostering growth opportunities for both companies.

Strategic Partnership

Furthermore, UPC and KP have agreed to collaborate on the establishing of a medical product research and development center, which will be named Universe Hanhe Medical Research Institute Co., Ltd. Scaffolding by favorable policy treatment from the Chinese government, UPC will make use of its R&D capacity and medicinal resources, while KP will utilize its quality control standards and advanced technologies. Together the two will pool resources towards the development of expanding their portfolio of medical products.

Joint Venture Facility

According to the LOI, the achievement of specific strategic goals will lead to the collaborative construction of a manufacturing facility in accordance with the market access requirements from Japan’s Pharmaceutical and Medical Devices Agency (PMDA). The companies will collaborate to ensure the facility will be recognized as a qualified foreign manufacturer of pharmaceutical products, as well as facilitate PMDA certification as a Chinese medicine brand.

About UPC

UPC is a pharmaceutical producer and distributor in China that specializes in traditional Chinese medicine derivative products. Its target consumer audience is the elderly, with the aim of addressing physical conditions through the aging process and to facilitate the promotion of their general well-being. With the company’s products being sold in 30 provinces in China, it also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies.

Future Outlook for UPC

Armed with the expanded pool of resources from its ongoing partnership, UPC is poised to capitalize on the opportunities afforded to it and continue its trajectory of success. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

June 29, 2021
Universe Pharmaceuticals (UPC) stock is rising today: Things you need to know

Shares of Universe Pharmaceuticals (UPC) stock were rising today in response to the announcement of the full exercise of Underwriter’s over-allotment option by Univest Securities, LLC for its client Pharmaceuticals INC. UPC stock price saw a push of 28.68% to reach $5.16 a share at the time of this writing. At the previous trading session, UPC stock was red and closed with an 8.24% drop. Let’s deep dive to explore more of it.

What’s happening?

Today’s news about the UPC stock explains that Univest Securities, LLC has exercised in full of its Underwriter’s over-allotment option to purchase 750,000 additional shares of its common stock for its client Universe Pharmaceuticals INC. The public offering price for this offering was $5.00 per share and it resulted in the additional gross proceeds worth $3.75 million. Now the total number of sold shares of UPC stock in this offering reached 5.75 million and gross proceeds surged to $28.75 million. Back on March 26, 2021, Univest closed the initial public offering for its client Universe Pharmaceuticals of 5 million shares of its common stock which was previously announced on March 23, 2021.

Use of Proceeds:

UPC stock has the plan to use proceeds from this offering in the advancement of manufacturing facilities as well as for research and development purposes. Part of these proceeds will be used for marketing, branding, general and other cooperate purposes.

About UPC stock:

Universe Pharmaceuticals INC (UPC), a subsidiary of Sununion Holding Group Limited, is the manufacturer, marketer, distributor, and seller of traditional Chinese medicine products in the Republic of China.UPC’s core focus is to cure elders suffering from various chronic diseases. Furthermore, UPC is also the seller of third-party producer’s products including biomedical drugs, medical instruments as well as traditional Chinese medicine products.UPC was founded in 2019 and is in Jiangxi, China.

Conclusion

Investors are responding to the news announced by the UPC stock, but no one knows how long this trend will continue. Proceeds from the offering will help Universe Pharmaceutical in its various operational as well as marketing areas. In a nutshell, investors having long-term prospects need to do analyze UPC fundamentals, balance sheet, and development prospects before adding them to their portfolio.

April 1, 2021
Why Universe Pharmaceuticals Inc (UPC) stock rallied in Pre-Market today?

Shares of Universe Pharmaceuticals Inc (UPC) were soaring in Monday’s pre-market trading session. UPC stock price saw a boom of 83.54% in today’s pre-market to reach $7.47 a share as of this writing. The previous closing price of UPC stock was $4.07 representing a 0.49% gain. Let’s try to figure out the reason behind this bull.

What’s happening?

We find no news in today’s date by the UPC stock, no earnings report or analyst upgrades to justify this bull however on March 26, 2021, Univest Securities, LLC did announce the closure of an initial public offering (IPO) for its client Universe Pharmaceuticals Inc.This initial public offering of 5,000,000 ordinary shares was announced by the Universe Securities, LLC on March 23, 2021, at a public price of US$5.00 per ordinary share of the UPC stock.

This IPO resulted in US$25 million in the aggregate gross proceeds without deducting the offering-related expenses and the underwriting discounts. Furthermore, the underwriter has been granted a 45-day option to buy additional 750,000 shares of UPC stock under this public offering. The trading of ordinary shares of UPC stock began on March 23, 2021.

UPC stock Future Plans

Universe stock is planning to make use of these proceeds in various of its operational areas as well as for the growth in its manufacturing facilities. This revenue will help the UPC stock for the advancement in its research and development fields and will support the brand awareness, marketing, and advertisement of the Universe Stock. Some part of this amount will be used for UPC’s working capital and general corporate purposes.

About Universe Pharmaceuticals Inc

Universe Pharmaceuticals INC(UPC), a subsidiary of Sununion Holding Group Limited, is mainly working in the areas of research, development, marketing, and selling of traditional Chinese Medicine products in the Republic of China. Main focus of the UPC is the treatment of chronic diseases in the elders.UPC was founded in 2019 and its headquarter are located in Jiangxi, China.

Conclusion:

UPC stock is enjoying the bullish sentiment in the stock market despite the absence of any specific news by the Universe stock.UPC management is well aware of the future goals related to its development and expansion. Hence it is better for investors eyeing UPC stock to perform both technical and fundamental analysis before taking any decision.

March 29, 2021